Back to results
US 2023/0142883 A1Published application
Compounds and uses thereof
AssigneeFoghorn Therapeutics Inc.
InventorsSabine K. RUPPEL, Zhaoxia Yang, Jason T. Lowe, Johannes H. Voigt, Matthew Russell Netherton
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.
Claims33
A compound having the structure of Formula I:
- A-L-B Formula I,
- wherein
- A is:
- wherein
- A1 is a bond between A and L;
- R4 is H, optionally substituted C1-C6 alkyl, optionally substituted C2-C9 alkenyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C10 carbocyclyl;
- R5 is H, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, or optionally substituted C6-C10 aryl;
- R6a is H, halogen, cyano, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C9 alkenyl, optionally substituted C2-C9 heteroalkenyl, hydroxy, thiol, or optionally substituted amino;
- R6b is H, halogen, cyano, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C9 alkenyl, optionally substituted C2-C9 heteroalkenyl, hydroxy, thiol, or optionally substituted amino;
- or R6a and R6b, together with the carbon atoms to which each is attached, combine to form optionally substituted C6-C10 aryl or optionally substituted C2-C9 heteroaryl;
- s is 0, 1, 2, 3, or 4;
- each R9 is, independently, halogen, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C10 carbocyclyl, optionally substituted C2-C9 heterocyclyl, optionally substituted C6-C10 aryl, optionally substituted C2-C9 heteroaryl, optionally substituted C2-C9 alkenyl, optionally substituted C2-C9 heteroalkenyl, hydroxy, thiol, or optionally substituted amino;
- B is:
- wherein
- A2 is a bond between the degradation moiety and the linker,
- v1 is 0, 1, 2, 3, 4, or 5;
- u1 is 1, 2, or 3;
- T1 is a bond or
- R5A is H, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
- each RJ1 is, independently, halogen, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
- JA is absent, O, optionally substituted amino, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
- and
- J is absent, optionally substituted C3-C10 carbocyclylene, optionally substituted C6-C10 arylene, optionally substituted C2-C9 heterocyclylene, or optionally substituted C2-C9 heteroarylene;
- L is:
- A1-(E1)-(F1)-(C3)m-(E3)n-(F2)o1-(F3)o2-(E2)p-A2, Formula II
- wherein
- A1 is a bond between the linker and A;
- A2 is a bond between B and the linker,
- each of m, n, o1, o2, and p is, independently, 0 or 1;
- each of E1 and E2 is, independently, O, S, NRN, optionally substituted C1-19 alkylene, optionally substituted C2-10 alkenylene, optionally substituted C2-10 alkynylene, optionally substituted C2-C10 polyethylene glycol, or optionally substituted C1-10 heteroalkylene;
- E3 is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, O, S, or NRN;
- each RN is, independently, H, optionally substituted C1-4 alkyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, optionally substituted C2-6 heterocyclyl, optionally substituted C6-12 aryl, or optionally substituted C1-7 heteroalkyl;
- C3 is carbonyl, thiocarbonyl, sulphonyl, or phosphoryl;
- and
- each of F1, F2, and F3 is, independently, optionally substituted C3-C10 carbocyclylene, optionally substituted C2-10 heterocyclylene, optionally substituted C6-C10 arylene, or optionally substituted C2-C9 heteroarylene,
- or a pharmaceutically acceptable salt thereof.
33 more elements
The compound of 19, wherein the C2-C6 heterocyclylene is spirocyclic.
Dependencies are inferred from the claim text.